AAOMS Annual Meeting

The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.

The US Food and Drug Administration recently approved a new glucagon-like peptide-1 receptor antagonist for improving glycemic control in patients with type 2 diabetes.

The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.

The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.

The FDA has approved a new option for the treatment of life-threatening allergic reactions, including anaphylaxis, in infants and young children.

After 2 clinical trials demonstrated its safety and efficacy, the US Food and Drug Administration approved the first complete HIV treatment regimen containing only 2 drugs.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.

After clinical trials demonstrated its efficacy, the US Food and Drug Administration approved a new treatment option for patients with hemophilia A who have Factor VIII inhibitors.

After a clinical trial demonstrated its efficacy, the FDA approved a new treatment option for adult and pediatric patients with a rare, inherited metabolic disorder.